These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20502137)

  • 21. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine.
    Munro J; Matthiasson P; Osborne S; Travis M; Purcell S; Cobb AM; Launer M; Beer MD; Kerwin R
    Acta Psychiatr Scand; 2004 Oct; 110(4):292-8. PubMed ID: 15352931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia.
    Kasper S
    Int Clin Psychopharmacol; 2002 Dec; 17 Suppl 4():S19-26. PubMed ID: 12685918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amisulpride: its role in the therapeutic management of the schizophrenia patient. Conclusions.
    Peuskens J
    Acta Psychiatr Scand Suppl; 2000; 400():28-9. PubMed ID: 10823309
    [No Abstract]   [Full Text] [Related]  

  • 24. Plasma amisulpride levels in schizophrenia or schizoaffective disorder.
    Bergemann N; Kopitz J; Kress KR; Frick A
    Eur Neuropsychopharmacol; 2004 May; 14(3):245-50. PubMed ID: 15056484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study.
    Müller MJ; Regenbogen B; Sachse J; Eich FX; Härtter S; Hiemke C
    Pharmacopsychiatry; 2006 Mar; 39(2):41-6. PubMed ID: 16555163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia.
    Xiberas X; Martinot JL; Mallet L; Artiges E; Canal M; Loc'h C; Mazière B; Paillère-Martinot ML
    J Clin Psychopharmacol; 2001 Apr; 21(2):207-14. PubMed ID: 11270918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Blocking D2/D3 Receptors on Mismatch Negativity and P3a Amplitude of Initially Antipsychotic Naïve, First Episode Schizophrenia Patients.
    Düring S; Glenthøj BY; Oranje B
    Int J Neuropsychopharmacol; 2015 Oct; 19(3):pyv109. PubMed ID: 26453696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Functional role of dopamine D3 receptor in schizophrenia].
    Semba J
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Feb; 24(1):3-11. PubMed ID: 15027325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clozapine-induced myocarditis after long-term treatment: case presentation and clinical perspectives.
    Lang UE; Willbring M; von Golitschek R; Schmeisser A; Matschke K; Malte Tugtekin S
    J Psychopharmacol; 2008 Jul; 22(5):576-80. PubMed ID: 18308817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.
    Wetzel H; Gründer G; Hillert A; Philipp M; Gattaz WF; Sauer H; Adler G; Schröder J; Rein W; Benkert O
    Psychopharmacology (Berl); 1998 Jun; 137(3):223-32. PubMed ID: 9682999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amisulpride: from animal pharmacology to therapeutic action.
    Scatton B; Claustre Y; Cudennec A; Oblin A; Perrault G; Sanger DJ; Schoemaker H
    Int Clin Psychopharmacol; 1997 May; 12 Suppl 2():S29-36. PubMed ID: 9218165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clozapine with amisulpride for refractory schizophrenia.
    Agelink MW; Kavuk I; Ak I
    Am J Psychiatry; 2004 May; 161(5):924-5. PubMed ID: 15121665
    [No Abstract]   [Full Text] [Related]  

  • 33. Amisulpride augmentation of clozapine in refractory schizophrenia.
    Chiu HW; Ku YC; Li TC; Huang HT
    J Neuropsychiatry Clin Neurosci; 2011; 23(3):E15. PubMed ID: 21948906
    [No Abstract]   [Full Text] [Related]  

  • 34. Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study.
    Surguladze S; Patel A; Kerwin RW; Knapp M; Travis MJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):517-22. PubMed ID: 15866352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clozapine augmented with amisulpride in 3 cases of treatment-resistant early- and very early-onset schizophrenia.
    Tufan AE; Yalug I
    J Clin Psychopharmacol; 2013 Aug; 33(4):572-4. PubMed ID: 23764685
    [No Abstract]   [Full Text] [Related]  

  • 36. Amisulpride: its role in the therapeutic management of the schizophrenic patient. Introduction.
    Darcourt G
    Acta Psychiatr Scand Suppl; 2000; 400():5-6. PubMed ID: 10823304
    [No Abstract]   [Full Text] [Related]  

  • 37. Acute weight gain induced by amisulpride monotherapy in a first-episode schizophrenic patient.
    Papadimitriou GN; Theleritis CG; Dikeos DG; Psarros CJ; Soldatos CR
    Int Clin Psychopharmacol; 2006 May; 21(3):181-4. PubMed ID: 16528141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consensus on the use of substituted benzamides in psychiatric patients.
    Racagni G; Canonico PL; Ravizza L; Pani L; Amore M
    Neuropsychobiology; 2004; 50(2):134-43. PubMed ID: 15292667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blonanserin, an antipsychotic and dopamine D₂/D₃receptor antagonist, and ameliorated alcohol dependence.
    Takaki M; Ujike H
    Clin Neuropharmacol; 2013; 36(2):68-9. PubMed ID: 23503552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of acute and repeated administration of amisulpride, a dopamine D2/D3 receptor antagonist, on the electrical activity of midbrain dopaminergic neurons.
    Di Giovanni G; Di Mascio M; Di Matteo V; Esposito E
    J Pharmacol Exp Ther; 1998 Oct; 287(1):51-7. PubMed ID: 9765321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.